BACKGROUND AND PURPOSE: Iodinated contrast media (Xenetix®, Ultravist®, Omnipaque®, Visipaque® and Iomeron®) used for computed tomography (CT) may decrease fibrinolysis by recombinant tissue plasminogen activator (rt-PA). We hypothesized that receiving iodinated contrast media before rt-PA may impair thrombolysis as measured by a new model system.
METHODS: Whole blood from Wistar Kyoto rats (n = 10) was obtained and allowed to form blood clots. Thrombolysis was performed by placing individually the prepared clots into 15 mL tubes and adding 5 mL saline buffer, 100μg rt-PA and a different contrast media; adjusting the quantity of iodine to either 30 mg or 60 mg. The thrombolytic efficacy was quantified by measuring the optical density (OD415) of the supernatant at different time points, namely at 0, 30, 60, and 90 min.
RESULTS: There was a significant decrease in clot lysis efficiency observed in presence of iodine containing contrast media comparing to positive control group. Moreover, when the quantity of iodine was increased from 30 mg to 60 mg; the dissolution rate downturned with additional ∼50%.
CONCLUSION: In conclusion, our study suggests that high dose of iodine potentially could negatively affect the efficiency of the thrombolytic therapy performed by rt-PA.
AspelinP., StaculF., ThomsenH.S., MorcosS.K. and van der MolenA.J., Members of the contrast media safety committee of the European society of urogenital R. Effects of iodinated contrast media on blood and endothelium, European Radiology16(5) (2006), 1041–1049.
2.
DehmerG.J., GresalfiN., DalyD., OberhardtB. and TateD.A., Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents, Journal of the American College of Cardiology25(5) (1995), 1069–1075.
3.
ChesebroJ.H., KnatterudG., RobertsR., BorerJ., CohenL.S., DalenJ., et al., Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation76(1) (1987), 142–154.
4.
HerasM., ChesebroJ.H., GershB.G., HolmesD.R., MockM.B. and FusterV., Emergency thrombolysis in acute myocardial infarction, Annals of Emergency Medicine17(11) (1988), 1168–1175.
5.
DzialowskiI., PuetzV., BuchanA.M., DemchukA.M., HillM.D. and Calgary StrokeP., Does the application of X-ray contrast agents impair the clinical effect of intravenous recombinant tissue-type plasminogen activator in acute ischemic stroke patients?Stroke43(6) (2012), 1567–1571.
6.
MacdougallN.J., McVerryF., BairdS., BairdT., TeasdaleE. and MuirK.W., Iodinated contrast media and cerebral hemorrhage after intravenous thrombolysis, Stroke42(8) (2011), 2170–2174.
7.
YangV.C., NaikS.S., SongH., DombkowskiA.A., CrippenG. and LiangJ.F., Construction and characterization of a t-PA mutant for use in ATTEMPTS: A drug delivery system for achieving targeted thrombolysis, Journal of Controlled Release: Official Journal of the Controlled Release Society110(1) (2005), 164–176.
8.
StiefT.W., BunderR., RichterA., MaischB., RenzH. and FareedJ., In vitro simulation of therapeutic plasmatic fibrinolysis, Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis9(3) (2003), 211–220.
9.
KomorowiczE., KolevK., LerantI. and MachovichR.Flow rate-modulated dissolution of fibrin with clot-embedded and circulating proteases, Circulation Research82(10) (1998), 1102–1108.
10.
BastaG., LupiC., LazzeriniG., ChiarelliP., L’AbbateA. and RovaiD., Therapeutic effect of diagnostic ultrasound on enzymatic thrombolysis. An in vitro study on blood of normal subjects and patients with coronary artery disease, Thrombosis and Haemostasis91(6) (2004), 1078–1083.
11.
BeltramiE. and JestyJ., Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: Application to the feedbacks of blood coagulation, Proceedings of the National Academy of Sciences of the United States of America92(19) (1995), 8744–8748.
12.
AnandS. and DiamondS.L., Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction, Circulation94(4) (1996), 763–774.
13.
YuX., SongS.K., ChenJ., ScottM.J., FuhrhopR.J., HallC.S., et al., High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent, Magnetic Resonance in Medicine44(6) (2000), 867–872.
14.
WinterP.M., ShuklaH.P., CaruthersS.D., ScottM.J., FuhrhopR.W., RobertsonJ.D., et al., Molecular imaging of human thrombus with computed tomography, Academic Radiology12(Suppl 1) (2005), S9–S13.
15.
LorenM., Garcia FradeL.J., TorradoM.C. and NavarroJ.L., Thrombus age and tissue plasminogen activator mediated thrombolysis in rats, Thrombosis research56(1) (1989), 67–75.
16.
VorosE., ChoM., RamirezM., PalangeA.L., De RosaE., KeyJ., et al., TPA immobilization on iron oxide nanocubes and localized magnetic hyperthermia accelerate blood clot lysis, Advanced Functional Materials25(11) (2015), 1709–1718.
17.
KrzywinskiM. and AltmanN., Points of view: Designing comparative experiments, Nature Methods11(6) (2014), 597–598.
18.
ColucciM., ScopeceS., GelatoA.V., DimonteD. and SemeraroN., In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis–study in healthy subjects and correlation with blood fibrinolytic parameters, Thrombosis and Haemostasis77(4) (1997), 725–729.
19.
TrusenB., RiesM., ZenkerM., RauhM., BeinderE., KeuperH., et al., Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA), Seminars in Thrombosis and Hemostasis24(6) (1998), 599–604.
20.
SicaG.T., JiH. and RosP.R., CT and MR imaging of hepatic metastases, AJR American Journal of Roentgenology174(3) (2000), 691–698.
21.
GleesonT.G. and BulugahapitiyaS., Contrast-induced nephropathy, AJR American Journal of Roentgenology183(6) (2004), 1673–1689.
22.
GabrielD.A., JonesM.R., ReeceN.S., BoothroydE. and BashoreT., Platelet and fibrin modification by radiographic contrast media, Circulation Research68(3) (1991), 881–887.
23.
GrangerC.B., GabrielD.A., ReeceN.S., BoothroydE., HardingM.B., HarrisonJ.K., et al., Fibrin modification by ionic and nonionic contrast media during cardiac catheterization, The American Journal of Cardiology69(8) (1992), 821–823.
24.
GerkU., KrugerA., FrankeR.P. and JungF., Effect of radiographic contrast media (Iodixanol, Iopromide) on hemolysis, Clin Hemorheol Microcirc58(1) (2014), 171–174.
25.
KaessmeyerS., SehlJ., Khiao InM., HieblB., MerleR., JungF., et al., Organotypic soft-tissue co-cultures: Morphological changes in microvascular endothelial tubes after incubation with iodinated contrast media, Clin Hemorheol Microcirc64 (2016), 391–402.
26.
SongJ., WangX., XuX., JiaB., ZhengQ., KaW., et al., The effects of non-ionic contrast medium on the hemorheology in vitro and in vivo, Clin Hemorheol Microcirc58(3) (2014), 385–393.
